Spinocerebellar Ataxia Type 2
14
2
5
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
21%
3 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
Integrated Functional Evaluation of the Cerebellum
Troriluzole in Adult Participants With Spinocerebellar Ataxia
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Instrumented Data Exchange for Ataxia Study
Open Pilot Trial of BHV-4157
Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)
Study of CAD-1883 for Spinocerebellar Ataxia
Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia
Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia
Biomarkers in Autosomal Dominant Cerebellar Ataxia